FY2026 Earnings Estimate for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Femasys in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.40) per share for the year, down from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at $0.12 EPS.

Femasys Stock Up 2.6 %

FEMY opened at $1.60 on Monday. The company has a market cap of $36.64 million, a price-to-earnings ratio of -1.98 and a beta of -2.85. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys has a one year low of $0.86 and a one year high of $1.84. The business’s fifty day moving average is $1.39 and its two-hundred day moving average is $1.22.

Hedge Funds Weigh In On Femasys

Several hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd lifted its position in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after acquiring an additional 17,473 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Femasys in the 4th quarter valued at $25,000. Northern Trust Corp lifted its holdings in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after acquiring an additional 37,675 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Femasys during the 4th quarter worth $30,000. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.